Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HOLX 
Hologic Inc (HOLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: HOLX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $75
1 Year Target Price $75
| 3 | Strong Buy |
| 3 | Buy |
| 14 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.01% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 16.45B USD | Price to earnings Ratio 30.67 | 1Y Target Price 75 |
Price to earnings Ratio 30.67 | 1Y Target Price 75 | ||
Volume (30-day avg) 20 | Beta 0.63 | 52 Weeks Range 51.90 - 84.39 | Updated Date 11/1/2025 |
52 Weeks Range 51.90 - 84.39 | Updated Date 11/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-03 | When After Market | Estimate 1.1 | Actual - |
Profitability
Profit Margin 13.79% | Operating Margin (TTM) 25.48% |
Management Effectiveness
Return on Assets (TTM) 6.69% | Return on Equity (TTM) 11.38% |
Valuation
Trailing PE 30.67 | Forward PE 14.93 | Enterprise Value 15747893440 | Price to Sales(TTM) 4.07 |
Enterprise Value 15747893440 | Price to Sales(TTM) 4.07 | ||
Enterprise Value to Revenue 3.9 | Enterprise Value to EBITDA 14.44 | Shares Outstanding 222566511 | Shares Floating 220370800 |
Shares Outstanding 222566511 | Shares Floating 220370800 | ||
Percent Insiders 0.85 | Percent Institutions 100.44 |
Upturn AI SWOT
Hologic Inc
Company Overview
History and Background
Hologic Inc. was founded in 1985. Initially focused on bone densitometry, it has grown through acquisitions and product development to become a leader in women's health. Significant milestones include the acquisition of Cytyc Corporation in 2007 and Gen-Probe in 2012, expanding its diagnostics capabilities.
Core Business Areas
- Diagnostics: Develops and manufactures diagnostic products for a range of applications, including women's health, molecular diagnostics, and blood screening.
- Breast Health: Offers a comprehensive suite of breast health solutions, including mammography systems, breast biopsy devices, and surgical products.
- Surgical: Provides minimally invasive gynecological surgical products, including hysteroscopes and tissue removal systems.
Leadership and Structure
Stephen P. MacMillan is the Chairman, President, and CEO. The organizational structure is typical of a large publicly traded company, with functional departments reporting to executive leadership.
Top Products and Market Share
Key Offerings
- Product Name 1: Cervical Cancer Screening: Hologic's ThinPrep Pap test is a leading liquid-based cytology test for cervical cancer screening. Estimated market share around 40%. Competitors: Roche (COBAS), BD (SurePath).
- Product Name 2: Mammography Systems: Hologic's 3D mammography (tomosynthesis) systems are widely used for breast cancer screening. They hold a substantial portion of the market. Market share is approximately 35%. Competitors: GE Healthcare (GE), Siemens Healthineers (SIEGY).
- Product Name 3: Aptima Assays: These are molecular diagnostic assays used to detect various infectious diseases. Competition includes Roche, Abbott, and Siemens. Market share estimated at 20%.
Market Dynamics
Industry Overview
The medical device and diagnostics industry is characterized by innovation, regulatory oversight, and evolving healthcare needs. Growth is driven by aging populations, increased disease prevalence, and technological advancements.
Positioning
Hologic is a leader in women's health, with a strong portfolio of diagnostic and surgical products. Its competitive advantages include a strong brand, innovative technology, and established customer relationships.
Total Addressable Market (TAM)
The TAM for women's health diagnostics and devices is estimated to be over $30 billion. Hologic is well-positioned within this TAM, targeting key areas such as breast cancer screening, cervical cancer screening, and minimally invasive surgery.
Upturn SWOT Analysis
Strengths
- Strong Brand Reputation
- Innovative Technology
- Established Market Position in Women's Health
- Diverse Product Portfolio
- Effective Sales and Marketing Organization
Weaknesses
- Reliance on a Few Key Products
- Exposure to Reimbursement Changes
- Potential for Product Liability Claims
- Competition in Mature Markets
Opportunities
- Expanding into Emerging Markets
- Developing New Diagnostic and Therapeutic Products
- Acquiring Complementary Businesses
- Leveraging Digital Health Technologies
- Increasing Demand for Preventative Care
Threats
- Increased Competition
- Regulatory Changes
- Economic Downturns
- Technological Disruption
- Healthcare Cost Containment Pressures
Competitors and Market Share
Key Competitors
- ROSE.SW
- SIEGn.DE
- ABT
- BDX
Competitive Landscape
Hologic faces intense competition from larger, more diversified medical device companies. Its competitive advantages include its focus on women's health, innovative technology, and strong brand.
Major Acquisitions
Biotheranostics
- Year: 2021
- Acquisition Price (USD millions): 230
- Strategic Rationale: Expanded Hologic's oncology testing portfolio.
Somatex Medical Technologies GmbH
- Year: 2021
- Acquisition Price (USD millions): 64
- Strategic Rationale: Expanded Hologic's breast biopsy capabilities.
Growth Trajectory and Initiatives
Historical Growth: Hologic's growth has been driven by organic product development and acquisitions. Future growth is dependent on new product launches and market expansion.
Future Projections: Analyst estimates can be found on financial websites such as Yahoo Finance or Bloomberg.
Recent Initiatives: Recent initiatives include product launches, acquisitions, and partnerships.
Summary
Hologic is a strong player in the women's health market, underpinned by its focus and innovative products. They have seen growth through strategic acquisitions. Reimbursement pressures and competition pose challenges to Hologic's growth. They need to be aware of disruptive technologies in diagnostics.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Hologic Inc. SEC Filings (10-K, 10-Q)
- Company Press Releases
- Analyst Reports (e.g., from Yahoo Finance, Bloomberg)
- Industry Reports (e.g., from market research firms)
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change. Consult a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hologic Inc
Exchange NASDAQ | Headquaters Marlborough, MA, United States | ||
IPO Launch date 1990-06-21 | Chairman, CEO & President Mr. Stephen P. MacMillan | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 7063 | Website https://www.hologic.com |
Full time employees 7063 | Website https://www.hologic.com | ||
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.